A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed/refractory multiple myeloma who previously received adequate but uneffective standard treatments.

Trial Details

NCT ID
NCT06999031
Phase
EARLY_PHASE1
Sponsor
The First Affiliated Hospital of Nanchang University
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • Aged 18-75 years (inclusive of 18 and 75 years old), gender not limited;
  • Subject has received at least 3 lines of therapy, including at least proteasome inhibitors (PIs) and immunomodulatory therapy (IMiD); disease relap…
  • Subjects whose tumor specimens were positive for BCMA expression on the membrane surface of plasma cells by immunohistochemistry (IHC) or flow cyto…
  • One of the following is met (all data below are compared to the obtained minimum values):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →